{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076595","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.796998+00:00","generated_at":"2026-05-15T23:40:15.414416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline","bullets":["Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).","Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.","FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.","FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.","Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076595","json":"https://secwatch.observer/filing/0001193125-26-076595.json","markdown":"https://secwatch.observer/filing/0001193125-26-076595.md","text":"https://secwatch.observer/filing/0001193125-26-076595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/0001193125-26-076595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/orgo-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:40:15.414416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}